Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1/2 2Phase 1 2Phase 3 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Oligodendroglioma 1Liver Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × irofulven × Clear all
NCT00374660 2021-12-08

Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

Eisai Inc.

Phase 1/2 Completed
63 enrolled
Gastrointestinal

Liver Neoplasms

NCT00012038 2013-06-24

Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡